Skip to main content

Sagimet Biosciences Inc.

corporate_fare Company Profile

Sagimet Biosciences Inc.

SGMT·NASDAQ·Life Sciences·CIK 0001400118

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics called fatty acid synthase (FASN) inhibitors. These inhibitors target dysfunctional metabolic and fibrotic pathways in diseases caused by the overproduction of the fatty acid, palmitate. The company's lead drug candidate is denifanstat, an oral, once-daily pill and selective FASN inhibitor. Denifanstat is currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer. Sagimet Biosciences Inc. also has a second FASN inhibitor, TVB-3567, which is a potent and selective small molecule FASN inhibitor in development for acne. The company's FASN inhibitors aim to address MASH, an aggressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by excess fat buildup in the liver unrelated to alcohol consumption. A 2023 study indicated MASH affected over 265 million people worldwide in 2019. Denifanstat targets multiple drivers of MASH by reducing steatosis, inflammation, and fibrosis. In the Phase 2b FASCINATE-2 clinical trial, denifanstat met all primary and multiple secondary endpoints in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52. Topline results were announced in January 2024, and trial results were published in The Lancet Gastroenterology & Hepatology in October 2024.

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for SGMT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for SGMT spans 10-Q, 8-K, 424B5, 4.

Recent high-impact activity:

  • Sagimet Posts 31c Quarterly Loss as Phase 3 R&D Spending Jumps 68%
  • Sagimet Q3 Loss Widens to $19.1M as AURORA Phase 3 Ramps; $275.8M Cash Plus $107.5M October Net
  • Sagimet Shares Fall as $115M Offering Closes, Acne Drug Data Digested
  • Sagimet Secures $107.5M in Underwritten Offering to Advance Phase 3 Acne Trial
  • Sagimet Prices $115M Offering at $10.00 — Net Proceeds $107.5M to Fund Phase 3 Acne Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$51.04M
Diluted EPS
-$1.58
Op. Cash Flow
-$45.65M
Operating Income
-$56.89M
Cash & Equivalents
$35.02M
Debt / Equity
0.00×
Shares Outstanding
32.35M sh
Source: 10-K · filed 2026-03-11 · accession 0001104659-26-026140

Short Interest & Short Volume

10.47 days to cover

FINRA reported short interest of 12,172,501 shares in SGMT as of the October 30, 2026 settlement, a 5.6% increase from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 43.0% of SGMT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,172,501 shares as of October 30, 2026
Change vs prior period▲ 5.6%
Days to cover10.47 at avg daily volume of 1,162,145
Daily short volume (FINRA facilities)43.0% of 412,749 shares on November 20, 2026
5-day average short volume49.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for SGMT, detected from its recent SEC filings · based on capital-structure filings through 2026-09-30.

1 recent capital raiseATM program

Offering Priced at $10.00 · Net Proceeds $107.5M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with S →
$9.07 -0.11% today
52-week range · as of 2026-11-12 $4.5 – $11.45
Market cap
$648.02M
Volume
1.5M (1.2× avg)
3-mo avg 1.2M
Live data · 2026-11-21 19:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SGMT - Latest Insights

SGMT
Nov 12, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $11.40
Real-time Price: $9.07 info
Change: -$2.33 (-20%) info
Market Cap: $648.02M info
SGMT
Nov 12, 2026, 7:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.40
Real-time Price: $9.07 info
Change: -$2.33 (-20%) info
Market Cap: $648.02M info
SGMT
Oct 01, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $9.07 info
Change: -$0.170 (-2%) info
Market Cap: $648.02M info
SGMT
Sep 30, 2026, 6:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $9.07 info
Change: -$0.960 (-10%) info
Market Cap: $648.02M info
SGMT
Sep 30, 2026, 5:53 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $9.07 info
Change: -$0.960 (-10%) info
Market Cap: $648.02M info
SGMT
Sep 30, 2026, 6:19 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.99
Real-time Price: $9.07 info
Change: -$0.920 (-9%) info
Market Cap: $648.02M info
SGMT
Sep 30, 2026, 6:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.43
Real-time Price: $9.07 info
Change: -$0.360 (-4%) info
Market Cap: $648.02M info
SGMT
Sep 30, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.43
Real-time Price: $9.07 info
Change: -$0.360 (-4%) info
Market Cap: $648.02M info
SGMT
Aug 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.21
Real-time Price: $9.07 info
Change: -$1.14 (-11%) info
Market Cap: $648.02M info
SGMT
Aug 17, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $10.43
Real-time Price: $9.07 info
Change: -$1.36 (-13%) info
Market Cap: $648.02M info
SGMT
Aug 13, 2026, 7:27 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $9.47
Real-time Price: $9.07 info
Change: -$0.400 (-4%) info
Market Cap: $648.02M info
SGMT
Aug 13, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $9.07 info
Change: -$0.410 (-4%) info
Market Cap: $648.02M info
SGMT
Aug 11, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $9.07 info
Change: -$0.130 (-1%) info
Market Cap: $648.02M info
SGMT
Aug 11, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $9.07 info
Change: -$0.130 (-1%) info
Market Cap: $648.02M info
SGMT
Aug 11, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.20
Real-time Price: $9.07 info
Change: -$0.130 (-1%) info
Market Cap: $648.02M info
SGMT
Jul 22, 2026, 4:05 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $7.05
Real-time Price: $9.07 info
Change: +$2.02 (+29%) info
Market Cap: $648.02M info
SGMT
Jun 03, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.86
Real-time Price: $9.07 info
Change: +$2.21 (+32%) info
Market Cap: $648.02M info
SGMT
May 12, 2026, 7:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.69
Real-time Price: $9.07 info
Change: +$1.38 (+18%) info
Market Cap: $648.02M info
SGMT
Apr 28, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.01
Real-time Price: $9.07 info
Change: +$1.06 (+13%) info
Market Cap: $648.02M info
SGMT
Apr 28, 2026, 6:02 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $7.90
Real-time Price: $9.07 info
Change: +$1.17 (+15%) info
Market Cap: $648.02M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets